Crossmark

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies

Crossref DOI link: https://doi.org/10.1007/s10072-019-03778-7

Published Online: 2019-03-01

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vita, Giuseppe https://orcid.org/0000-0002-5204-7826
Vita, Gian Luca

Stancanelli, Claudia

Gentile, Luca

Russo, Massimo

Mazzeo, Anna
License Information

Text and Data Mining valid from 2019-03-01
More Information

Article History

Received: 2 January 2019

Accepted: 16 February 2019

First Online: 1 March 2019

Compliance with ethical standards

:

: G.V. discloses having been on advisory board for Alnylam Therap., Akcea Therap, and Pfizer. He is also principal investigator in clinical trials sponsored by Alnylam Therap and Ionis Therap.